Brokerage Firm Rating on Mast Therapeutics (MSTX)

Mast Therapeutics (MSTX) : Zacks Investment Research ranks Mast Therapeutics (MSTX) as 3, which is a Hold recommendation. 4 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. The average broker rating of 4 research analysts is 1, which indicates as a Strong Buy.

Mast Therapeutics (MSTX) : Average target price received by Mast Therapeutics (MSTX) is $2.67 with an expected standard deviation of $2.08. The most aggressive target on the stock is $5, whereas the most downbeat target is $1. 3 financial analysts are currently covering the stock.


For the current week, the company shares have a recommendation consensus of Buy. Mast Therapeutics (NYSEMKT:MSTX): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $0.35 and $0.34 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $0.36. The buying momentum continued till the end and the stock did not give up its gains. It closed at $0.35, notching a gain of 0.95% for the day. The total traded volume was 1,305,097 . The stock had closed at $0.35 on the previous day.

In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the CFO of Mast Therapeutics, Inc., Roberts Brandi, had purchased 38,000 shares in a transaction dated on March 26, 2015. The transaction was executed at $0.5 per share with total amount equaling $19,000.

Mast Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops therapies for serious or life-threatening diseases with unmet needs. The Company leverages its Molecular Adhesion and Sealant Technology (MAST) platform, to develop MST-188 (vepoloxamer) Injection, the Companys lead product candidate. Vepoloxamer is being tested in a Phase III clinical study called EPIC for the treatment of vaso-occlusive crisis in patients with sickle cell disease. The Company also develops AIR001, a sodium nitrite solution for intermittent inhalation through nebulizer. AIR001 is being tested in multiple institution-sponsored Phase IIa clinical studies that provide the Company with data on AIR001s potential to treat patients with preserved ejection fraction (HFpEF).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.